External Link

You are now leaving the Grünenthal (IE) website. You will be re-directed to an external website. Grünenthal Pharma Ltd., Ireland accepts no responsibility for the content of other websites.

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. An integrated research and development company, we have an enviable track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation.

Grünenthal Pharma Ltd., Ireland, a wholly owned subsidiary of Grünenthal GmbH, was established in 2005. With headquarters in Dublin, the company distributes and markets pain and anti-infective products under an exclusive distribution agreement with Grünenthal GmbH.

Grünenthal Pharma Limited markets: Crestor®, Nebido®, Palexia Film Coated Tablets®, Palexia SR®, Qutenza®, Vimovo®, Nexium®, Versatis®, Zomig, Ixprim®, Ixprim Effervescent®, Zydol® (tramadol HCI) and Zydol SR®.

Mature man listening to music while resting after jogging

2019 Vimovo®

Launch of Vimovo®

2018 Qutenza®

Launch of the Qutenza® capsaicin patch, indicated for the management of neuropathic pain associated with postherpetic neuralgia (PHN).

Senior couple walking on the beach in fall season
Happy couple

2011 Palexia®

Launch of Palexia®: our tapentadol medication was the first innovative molecule in the centrally acting analgesic class approved in more than 25 years.

2011 Versatis®

Versatis® is launched, a topically acting lidocaine patch used for the treatment of neuropathic pain after herpes zoster. 

Versatis® is launched in the EU

2008 Ixprim®

Ixprim® the first fixed-dose analgesic containing paracetamol and a small dose of tramadol used for the treatment of acute pain is launched in Ireland. 

2005 Company Launch

Company launched to promote Zydol® and Zydol® SR 

Thalidomide

Thalidomide will always be a significant part of our company history.

Visit website
M-N/A-IE-12-25-0002 December 2025